|Bid||249.1100 x 100|
|Ask||249.2200 x 300|
|Day's Range||243.8700 - 249.4400|
|52 Week Range||184.5000 - 261.2700|
|PE Ratio (TTM)||7.77|
|Dividend & Yield||2.80 (1.17%)|
|1y Target Est||N/A|
The mental health biotech sub-sector includes companies developing drugs for ADHD, depression, bipolar disorder, schizophrenia, migraines, alzheimer's, and other central nervous system conditions. Due to growing public awareness, Todd Hagopian believes these stocks are reaching a tipping point.
I think caution is warranted if we rally again like this.
Jardiance (empagliflozin) is a part of the Boehringer Ingelheim and Eli Lilly’s (LLY) diabetes alliance.